Drug intelligence / Profile preview

HAC 22L

Development stage: Unknown
Lead developer: AbbVie
Administration: Subcutaneous, Percutaneous

Overview

HAC 22L is a next-generation hyaluronic acid-based dermal filler containing lidocaine, developed by AbbVie (Allergan Aesthetics). It is formulated as an injectable gel with a hyaluronic acid concentration of 22 mg/mL, designed for subcutaneous or supraperiosteal administration. The product is intended to treat facial volume deficits by providing a volumizing effect, specifically targeting areas such as the mid-face, chin, and jawline. As a medical device, HAC 22L works through physical space-filling to restore or augment facial contours and improve aesthetic appearance. It is currently being evaluated in clinical trials to assess its safety and effectiveness for various facial contouring indications.

Other names: HAC 22L InjectionHAC22L InjectionHAC-22L InjectionHAC 22L Dermal FillerHAC22L Dermal FillerHAC-22L Dermal Filler

Beyond the preview

Go deeper on HAC 22L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAC 22L.

Explore the full profile